FDMT News and Press, 4D Molecular Therapeutics Inc. From 12/17/25

2025-12-17 14:02:38 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AER...

2025-12-17 12:59:04 ET 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential December 17, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: 4D Molecular Therapeutics,...

Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2  Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data support 4D-710’s ...

EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to...

2025-11-21 19:43:25 ET 4D Molecular Therapeutics, Inc. (FDMT) Jefferies London Healthcare Conference 2025 November 18, 2025 4:00 AM EST... Read the full article on Seeking Alpha For further details see: 4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Heal...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for ...

EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to...

2025-11-17 06:17:17 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors 4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) 4D Molecu...

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to...

2025-11-10 08:15:30 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors 4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) 4D Molecu...